Browsing Tag

BXCL701

BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of…

Jason Junior Feb 15, 2022

BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging composite response rates in SCNC (33%) and adenocarcinoma (21%) cohorts Company plans to continue evaluation of BXCL701 combination as potentially differentiated approach for…

Health

BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with…

Jason Junior Sep 16, 2021

BXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma BXCL701 combination continues to exhibit favorable safety profile; patient enrollment continues…